ABT 8-K Current Reports

ABBOTT LABORATORIES 8-K Report, Corporate Update (Oct 21, 2026)

Abbott Laboratories (ABT) announced its intention to separate its global Nutrition business into an independent, publicly traded company. This strategic move aims to unlock distinct growth and value-creation opportunities for both the standalone Nutrition entity and the remaining Abbott healthcare business. The new Nutrition company is projected to have approximately $8.5 billion in annual sales and will focus on the rapidly growing healthy nutrition market with iconic brands like Similac, PediaSure, and Ensure. Following the separation, Abbott will continue as a diversified healthcare leader with approximately $42 billion in sales, concentrating on its higher-growth, innovation-driven portfolio in medical devices, diagnostics, and established medicines. The separation is anticipated to be completed by the end of 2027 and is structured as a tax-free distribution of shares to Abbott shareholders, who will then own stakes in both entities. This move is expected to allow for more aligned capital allocation and distinct strategic focus for each business.

Oct 21, 2026 8-K

Regulation FDOther EventsExhibits & Filings

ABBOTT LABORATORIES 8-K Report, Financial Results (Oct 21, 2026)

Abbott Laboratories (ABT) reported strong third-quarter 2026 results, with total reported sales increasing by 14.5% and comparable sales growing by 7.0%. The company reaffirms its full-year 2026 adjusted diluted earnings per share (EPS) guidance of $5.50 to $5.55, tightening the range. This performance was driven by broad-based growth across its key business segments, including Diagnostics and Medical Devices, with notable contributions from new product approvals and market expansions. The report also details significant progress in product innovation and regulatory approvals, including the FDA approval of Libre® Duo, a dual glucose-ketone sensor, and the CE Mark for the Amulet 360™ Left Atrial Appendage Occluder. These advancements, coupled with reaffirmed financial guidance, suggest continued positive momentum for Abbott Laboratories heading into the final quarter of the year.

Oct 21, 2026 8-K

ABBOTT LABORATORIES 8-K Report, Regulation FD Disclosure (Aug 20, 2026)

On August 20, 2026, Abbott Laboratories (ABT) disclosed agreements to resolve a portion of its litigation over its specialty preterm infant formulas. Under the agreements, Abbott will resolve the Gill case, a July 2024 Missouri jury verdict of $495 million that the Missouri Court of Appeals affirmed in May 2026, along with necrotizing enterocolitis (NEC) claims on behalf of roughly 2,000 additional infants, for an aggregate of approximately $670 million. Rather than continue appealing or pay the roughly $600 million Gill judgment plus accrued interest, Abbott chose to settle. The company stresses that the agreements are a compromise of disputed claims, not an admission of liability. The filing signals a potentially meaningful step toward containing a long-running overhang on the company's nutritionals business. Abbott cites recent favorable rulings, including a Seventh Circuit affirmance of a pretrial judgment in the first federal MDL bellwether case, a June 2026 Illinois appellate reversal of a $60 million verdict against Mead Johnson, and a March 2026 Florida dismissal based on the learned intermediary doctrine. Following the settlements, about 1,700 lawsuits involving roughly 12,700 infants remain pending. Abbott says that population includes claims it considers improper, such as claims naming both Abbott and Mead Johnson without identifying the formula used, claims involving infants diagnosed with NEC before receiving any formula, claims involving infants never diagnosed with NEC, and duplicate filings across jurisdictions, and that it continues working to eliminate them. For investors, the key takeaways are the size of the cash outlay relative to the company's scale, the absence of any admission of liability, and the remaining claim count, which means the litigation is not yet resolved. The filing does not disclose the accounting impact, timing of payments, or whether the settlement amount was already reserved, so investors should look to subsequent SEC reports for those details.

Aug 20, 2026 8-K

Leadership ChangesShareholder MattersCorporate Changes+1

ABBOTT LABORATORIES 8-K Report, Financial Results (Jul 16, 2026)

Abbott reported second-quarter 2026 net sales of $12.593 billion, up 13.0% on a reported basis and 4.8% on a comparable basis. The reported growth was driven mainly by the March 23, 2026 acquisition of Exact Sciences, which added $811 million to Q2 sales and is consolidated as Abbott's Cancer Diagnostics business. Comparable growth was led by Medical Devices (+8.4%, with Electrophysiology and Diabetes Care strong) and Established Pharmaceuticals (+8.7%), while Nutrition declined 3.6% and Rapid/Molecular Diagnostics fell 8.0% on lower respiratory virus testing. GAAP results were weaker. GAAP diluted EPS was $0.53 versus $1.01 a year earlier, and GAAP net earnings fell 47.8% to $928 million. The decline reflects $1.362 billion of after-tax specified items ($0.78 per share), including $385 million of legal reserves tied to an agreed-in-principle settlement, intangible amortization of $658 million (up from $420 million), and acquisition-related costs. Interest expense rose to $299 million from $50 million, and the effective GAAP tax rate was 39.1%, inflated by roughly $240 million of adjustments related to a previously recognized non-cash deferred tax benefit and about $110 million of net tax expense on prior-year tax positions. Adjusted diluted EPS rose 4.0% to $1.31 from $1.26. Management reaffirmed full-year 2026 comparable sales growth guidance of 6.5% to 7.5% and raised the adjusted diluted EPS range to $5.45 to $5.60 from $5.38 to $5.58, implying a modest midpoint increase. Third-quarter adjusted EPS is guided to $1.38 to $1.46. Management expects sales and earnings growth to accelerate in the second half. Abbott also returned $2.1 billion to shareholders in the quarter and declared its 410th consecutive quarterly dividend of $0.63 per share.

Jul 16, 2026 8-K

ABBOTT LABORATORIES 8-K Report, Executive Changes (Apr 27, 2026)

Abbott Laboratories (ABT) announced significant corporate governance updates following its Annual Shareholder Meeting on April 24, 2026. A key development is the approval of the Abbott Laboratories 2026 Incentive Stock Program, which will replace the previous 2017 program. This new program allows for a broad range of equity-based awards to employees and non-employee directors, with a maximum of 140,000,000 shares available, plus additional shares from the prior program's unused reserves. The program's adoption was overwhelmingly approved by shareholders, indicating strong support for the company's long-term incentive strategy. Additionally, the Board of Directors has been expanded from twelve to thirteen members, effective April 24, 2026. Shareholders also re-elected the entire slate of directors and ratified the appointment of Ernst & Young LLP as the company's auditors. The compensation of named executive officers was approved in an advisory vote, reflecting shareholder confidence in management's remuneration practices. These changes underscore Abbott's commitment to robust governance and aligning executive incentives with shareholder interests.

Apr 27, 2026 8-K

ABBOTT LABORATORIES 8-K Report, Corporate Update (Apr 17, 2026)

Abbott Laboratories (ABT) filed an 8-K on April 17, 2026 under Item 8.01 (Other Events) to disclose a proposed settlement of a consolidated shareholder derivative lawsuit, In re Abbott Laboratories Infant Formula Shareholder Derivative Litigation (N.D. Illinois, Case No. 1:22-cv-5513). The suit, previously disclosed in Abbott's 10-Ks for fiscal 2024 and 2025, names certain current and former directors and officers and alleges breach of fiduciary duty for failing to oversee infant formula manufacturing and sale, plus federal securities law violations tied to misstatements about the same subject matter. On April 10, 2026, the court preliminarily approved the settlement and scheduled a final settlement hearing. The settlement is non-monetary from Abbott's side in terms of payment to shareholders. Its principal term is that Abbott will maintain or adopt the corporate governance policies listed in Exhibit A to the stipulation and will commit the funds necessary to implement the governance elements. Lead Plaintiffs' counsel may request fees and expenses of up to $15.85 million, plus service awards of up to $15,000 per lead plaintiff, subject to court approval. The defendants deny wrongdoing, and the settlement would release the claims covered by the stipulation, including those arising from the February 2022 powdered infant formula recall and the Sturgis, Michigan and Casa Grande, Arizona facilities. For investors, the filing is a litigation-resolution update rather than a financial disclosure. It contains no reported earnings impact or reserve amount. The key dates are the May 18, 2026 deadline for shareholder objections and notices of intent to appear, and the June 4, 2026 final settlement hearing before Judge Sunil R. Harjani. Investors should note that the filing does not quantify the cost of the governance commitments, and the full terms are in the stipulation, which is available from the court.

Apr 17, 2026 8-K

ABBOTT LABORATORIES 8-K Report, Financial Results (Apr 16, 2026)

Abbott Laboratories reported first-quarter 2026 results on April 16, 2026, with GAAP net sales up 7.8% to $11.16 billion (3.7% on a comparable basis) and GAAP diluted EPS of $0.61, down from $0.76 a year earlier. Adjusted diluted EPS rose 5.5% to $1.15. The headline growth was helped by the March 23, 2026 acquisition of Exact Sciences, which contributed about $706 million of reported sales in the quarter. Excluding that acquisition and a one-time Structural Heart compensation payment that rolled off, underlying growth was modest. GAAP operating earnings fell 20.6%, driven by a 22.2% rise in SG&A to $3.74 billion, which includes about $444 million of acquisition-related expenses and accelerated stock-based compensation tied to the deal. Business performance was mixed. Medical Devices was the strongest segment, with comparable growth of 8.5%, led by Electrophysiology, Heart Failure and Rhythm Management, and continuous glucose monitor sales grew 7.6% on a comparable basis. Established Pharmaceuticals grew 9.0% comparably. Nutrition declined 7.7% comparably on lower volumes and strategic pricing actions taken in late 2025, and Rapid and Molecular Diagnostics fell 9.6% on a weaker respiratory season. Core Laboratory Diagnostics grew 3.3%, and Cancer Diagnostics (Exact Sciences) grew 13.4% comparably with Cologuard showing double-digit growth. Management raised its full-year 2026 framework to include the acquisition: comparable sales growth of 6.5% to 7.5% and adjusted EPS of $5.38 to $5.58, which includes $0.20 of acquisition dilution. Q2 2026 adjusted EPS is guided to $1.25 to $1.31. The company also declared its 409th consecutive quarterly dividend of $0.63 per share. Investors will want to watch whether the Nutrition decline reverses, whether Exact Sciences integration delivers the expected growth, and how the adjusted tax rate of 15.2% (versus 16.5% a year ago) holds through the year.

Apr 16, 2026 8-K

Material AgreementsFinancial EventsExhibits & Filings

ABBOTT LABORATORIES 8-K Report, Corporate Update (Mar 23, 2026)

On March 23, 2026, Abbott Laboratories (NYSE: ABT) completed its acquisition of Exact Sciences Corporation under the Agreement and Plan of Merger dated November 19, 2025. Merger Sub merged into Exact Sciences, which survives as a wholly owned Abbott subsidiary. Each Exact Sciences share was converted into the right to receive $105.00 in cash, without interest and less applicable withholding taxes. Exact Sciences' last day of trading on Nasdaq was March 20, 2026. Strategically, Abbott is adding a high-growth cancer screening and precision oncology franchise to its diagnostics business. Management cites a $60 billion U.S. cancer screening and precision oncology diagnostics market and says the deal adds a new growth vertical to Abbott's existing high-single-digit growth expectations. The acquired portfolio includes Cologuard (noninvasive colorectal cancer screening), Oncotype DX (breast cancer treatment guidance), Oncodetect (MRD testing), and Cancerguard (a multi-cancer early detection blood test), along with a next-generation pipeline. The 8-K is primarily a completion notice and does not disclose purchase price accounting, financing terms, pro forma financials, or updated guidance. Investors should look to Abbott's upcoming filings for the financial impact, integration costs, and synergy targets. The press release's forward-looking statements flag integration execution and synergy realization risks.

Mar 23, 2026 8-K

ABBOTT LABORATORIES 8-K Report, Material Agreement (Mar 9, 2026)

Abbott Laboratories (ABT) has announced the successful completion of a significant public offering of senior notes, raising a total of $20 billion. This substantial debt issuance comprises various tranches with different maturities and interest rates, ranging from floating rate notes due in 2029 to fixed-rate notes maturing in 2066. The primary purpose of this financing is to fund the acquisition of Exact Sciences Corporation, a strategic move that underscores Abbott's commitment to expanding its presence in the diagnostics and oncology sectors. While the offering provides the necessary capital for this major acquisition, investors should be aware of the conditional nature of the debt. The indenture includes a special mandatory redemption clause. If the Exact Sciences acquisition does not close by a specified date (currently the later of February 17, 2027, or an agreed-upon later date), or if Abbott decides not to proceed with the acquisition, the company will be obligated to redeem all outstanding notes at a premium (101% of principal plus accrued interest). This structure highlights the importance of the Exact Sciences deal for both Abbott's strategic direction and its financing obligations.

Mar 9, 2026 8-K

Material AgreementsExhibits & Filings

ABBOTT LABORATORIES 8-K Report, Material Agreement (Feb 26, 2026)

Abbott Laboratories (ABT) has filed an 8-K report detailing a significant material definitive agreement. On February 23, 2026, the company entered into a pricing agreement to issue and sell $20 billion in aggregate principal amount of senior notes. These notes comprise various fixed-rate tranches with maturities ranging from 2029 to 2066, as well as a floating rate note due in 2029. The offering is being conducted under a shelf registration statement and will be made pursuant to a prospectus supplement filed on February 25, 2026. The primary use of the net proceeds from this substantial debt offering is to fund the consideration for the acquisition of Exact Sciences Corporation. Additionally, proceeds will be used to repay Exact Sciences' existing indebtedness, cover associated fees and expenses, and for general corporate purposes, which may include further debt repayment. The closing of this notes offering is anticipated on March 9, 2026, subject to standard closing conditions.

Feb 26, 2026 8-K

ABBOTT LABORATORIES 8-K Report, Bylaw Amendment (Feb 20, 2026)

Abbott Laboratories (ABT) has filed a Current Report (8-K) on February 20, 2026, primarily detailing an amendment to its Board of Directors size. Effective April 24, 2026, the Board will be reduced from thirteen to twelve members. This change reflects a strategic decision by the Board of Directors and is a standard corporate governance adjustment. While not directly impacting current financial performance, changes in board composition can signal future strategic shifts or governance refinements. Investors should monitor any subsequent communications for insights into the rationale behind this reduction and its potential implications for board oversight and decision-making processes.

Feb 20, 2026 8-K

Leadership ChangesCorporate ChangesExhibits & Filings

ABBOTT LABORATORIES 8-K Report, Financial Results (Jan 22, 2026)

Abbott Laboratories reported fourth-quarter and full-year 2025 results on January 22, 2026, with sales of $11.46 billion in Q4 (up 4.4% reported, 3.0% organic) and $44.3 billion for the full year (up 5.7% reported, 5.5% organic). Adjusted diluted EPS rose 12% to $1.50 in Q4 and 10% to $5.15 for the full year, while GAAP diluted EPS was $1.01 in Q4 and $3.72 for 2025. The GAAP-to-adjusted gap reflects roughly $854 million of after-tax Q4 specified items, including $422 million of intangible amortization and a $165 million legal reserve. Full-year GAAP EPS is also depressed versus 2024, which was inflated by a $7.5 billion non-cash tax valuation allowance release, so year-over-year GAAP comparisons are not meaningful. The quarter was mixed by segment. Medical Devices was the clear bright spot, growing 10.4% organically in Q4 and 11.9% for the year, led by Electrophysiology, Heart Failure, Diabetes Care and Rhythm Management, with continuous glucose monitor sales of $2.0 billion in the quarter. Nutrition declined 9.1% organically in Q4 on lower volumes and strategic price actions, and Diagnostics fell 3.6% organically as COVID-19 testing revenue shrank and China faced volume-based procurement pressure. Established Pharmaceuticals grew 7.0% organically. Management's 2026 guidance calls for 6.5% to 7.5% organic sales growth and adjusted EPS of $5.55 to $5.80, roughly 10% growth at the midpoint, with Q1 2026 adjusted EPS of $1.12 to $1.18. Strategically, Abbott expects to close its pending acquisition of Exact Sciences in the second quarter of 2026, which would give it a foothold in cancer diagnostics. The company also launched its first pulsed field ablation system in the U.S. (Volt) and received CE Mark for a PFA-enabled catheter, strengthening its Electrophysiology position. The board declared a $0.63 quarterly dividend, the 408th consecutive quarterly payment and the 54th year of dividend increases.

Jan 22, 2026 8-K

ABBOTT LABORATORIES 8-K Report, Executive Changes (Dec 12, 2025)

Abbott Laboratories' December 12, 2025 Form 8-K is a routine governance filing with no financial results, guidance, or material operational disclosures. The company made two board-related changes: Dr. Nita Ahuja, M.D. was named to the Board of Directors, and the Board amended the by-laws to increase its authorized size from twelve to thirteen directors, effective the same day. The amended and restated by-laws are attached as Exhibit 99.1. For investors, the immediate financial impact is negligible. Board expansion and a new independent-style director addition are generally viewed as incremental governance events rather than signals about near-term performance, strategy, or capital allocation. The filing does not disclose Dr. Ahuja's committee assignments, compensation, or the background that prompted the board expansion, so those details would need to be checked in a subsequent proxy statement or a separate director appointment announcement. The by-laws amendment is limited to the board size provision in Article III, Section 2. The filing does not indicate any other substantive changes to shareholder rights, though the restated by-laws are long and include extensive proxy access, advance notice, and special meeting provisions that were not separately highlighted by the company. Investors interested in shareholder rights should review the full Exhibit 99.1 text against the prior by-laws.

Dec 12, 2025 8-K

Material AgreementsRegulation FDOther Events+1

ABBOTT LABORATORIES 8-K Report, Temporary Suspension of Trading Under Employee Benefit Plans (Nov 21, 2025)

Abbott Laboratories filed a Form 8-K on November 21, 2025 disclosing a temporary blackout period under its Stock Retirement Plan (U.S.) and Stock Retirement Plan (Puerto Rico), as required under ERISA Section 101(i)(2)(E). The blackout is needed because the plans are changing recordkeepers, the U.S. plan is changing trustees for certain funds, and the P.R. plan is changing custodians for certain funds. The blackout is expected to begin December 24, 2025 at 12 p.m. CST and end during the week of January 11, 2026. During the blackout, plan participants cannot change contribution rates, direct or diversify investments (including in Abbott common shares), make rollovers, obtain loans, take withdrawals or distributions, or view their plan accounts. This is a routine administrative event, but it is a period in which employees cannot sell Abbott stock held in their retirement accounts, and it coincides with the close of the fourth quarter, a time when investor attention on the company's earnings is high. The filing also notes that Abbott's directors and executive officers received a notice under Section 306 of Sarbanes-Oxley and Regulation BTR. These rules generally bar insiders from trading any Abbott equity security during the blackout, regardless of plan participation. This restriction is layered on top of Abbott's existing insider trading policy, which already blocks trades from December 15, 2025 until after the fourth-quarter earnings release. The filing contains no financial results or guidance, and the disclosure is procedural rather than a signal about company performance.

Nov 21, 2025 8-K

ABBOTT LABORATORIES 8-K Report, Material Agreement (Nov 20, 2025)

On November 19, 2025, Abbott Laboratories (ABT) entered into a definitive Agreement and Plan of Merger to acquire Exact Sciences (EXAS), a leader in cancer screening and precision oncology diagnostics, for $105.00 per share in cash. The deal implies a total equity value of approximately $21 billion and an enterprise value of about $23 billion, including roughly $1.8 billion of Exact Sciences net debt that Abbott's financing will absorb. The transaction was unanimously approved by both boards and is expected to close in the second quarter of 2026, subject to Exact Sciences shareholder approval, HSR antitrust clearance, and other regulatory approvals. Abbott also secured a commitment letter from Morgan Stanley Senior Funding for up to $20 billion of senior unsecured bridge loans. Strategically, Abbott is adding a high-growth vertical to its diagnostics franchise. Exact Sciences is projected to generate more than $3 billion in 2025 revenue with high-teens organic growth and a 70%+ adjusted gross margin profile. Management argues the deal is immediately accretive to Abbott's organic sales growth (about +50 basis points for the total company, +300 bps for Diagnostics) and gross margin (about +100 bps total, +700 bps for Diagnostics). Abbott expects the combination to double its addressable market in cancer diagnostics to more than $120 billion, with at least $100 million in annual pre-tax synergies by 2028. The financial trade-off is near-term EPS dilution: management projects adjusted EPS dilution of $0.20 in 2026 and $0.16 in 2027, with accretion expected in 2028 and beyond. Abbott expects to maintain its investment-grade credit rating and projects an initial 2026 adjusted gross debt-to-EBITDA ratio of about 2.7x after closing. Key risks include regulatory review, the Exact Sciences shareholder vote, potential competing offers, integration execution, and the possibility that expected synergies or growth are not realized.

Nov 20, 2025 8-K

ABBOTT LABORATORIES 8-K Report, Financial Results (Oct 15, 2025)

Abbott Laboratories reported third-quarter 2025 results on October 15, 2025, with reported sales of $11.369 billion, up 6.9% year over year. Organic growth was 5.5%, or 7.5% excluding COVID-19 testing-related sales, which have declined sharply as the pandemic transitioned to endemic demand. Growth was led by Medical Devices (up 14.8% reported, 12.5% organic), with double-digit gains in Diabetes Care, Electrophysiology, Rhythm Management, Heart Failure and Structural Heart. Nutrition grew 4.2% and Established Pharmaceuticals grew 7.5%, while Diagnostics declined 6.6% reported (down 7.8% organic, but up 0.4% excluding COVID-19 testing), with China volume-based procurement weighing on Core Laboratory results. On a GAAP basis, third-quarter diluted EPS was $0.94, flat year over year, and net earnings were $1.644 billion, down 0.1%. The GAAP result was held back by a higher tax rate of 24.6%, which includes roughly $160 million of adjustments tied to prior recognition of a significant non-cash deferred tax benefit. Adjusted diluted EPS was $1.30, up 7.4%, excluding $0.36 per share of specified items, primarily $420 million of intangible amortization plus restructuring and acquisition-related charges. Operating margin was 18.1% on a reported basis and 23.0% on an adjusted basis, a 40 basis point improvement. Management reaffirmed full-year 2025 organic sales growth guidance of 7.5% to 8.0% excluding COVID-19 testing (6.0% to 7.0% including it). It reaffirmed the midpoint of adjusted EPS guidance and narrowed the range to $5.12 to $5.18, implying double-digit growth at the midpoint. Abbott also declared its 407th consecutive quarterly dividend of $0.59 per share, payable November 17, 2025, to holders of record on October 15, 2025.

Oct 15, 2025 8-K

ABBOTT LABORATORIES 8-K Report, Financial Results (Jul 17, 2025)

Abbott Laboratories reported second-quarter 2025 results on July 17, 2025, with reported sales of $11.14 billion, up 7.4% year over year, and organic growth of 6.9% (7.5% excluding COVID-19 testing sales). Growth was broad-based, led by Medical Devices (+13.4% reported, +12.2% organic), with Diabetes Care (+20.2% reported, driven by continuous glucose monitors at $1.9 billion, up 21.4%), Heart Failure, Structural Heart and Electrophysiology posting double-digit gains. Nutrition grew 2.9% reported, and Diagnostics declined 1.0% reported (-1.4% organic) due to lower COVID-19 testing sales and China volume-based procurement, though ex-COVID tests Diagnostics grew 0.8%. Established Pharmaceuticals rose 6.9%. Profitability improved markedly. GAAP diluted EPS was $1.01, up 36.5%, while adjusted diluted EPS was $1.26, up 10.5% from $1.14. Reported gross margin reached 52.7% and adjusted gross margin 57.0%, each up about 100 basis points; adjusted operating margin was 22.9%. GAAP net earnings were helped by roughly $90 million of tax benefits from prior-year tax position resolutions, partly offset by about $100 million of adjustments related to a previously recognized non-cash deferred tax benefit. Intangible amortization fell 10.7% to $420 million. Management raised the low end of its guidance framework and reaffirmed its outlook: full-year 2025 organic sales growth of 7.5% to 8.0% excluding COVID-19 testing (6.0% to 7.0% including it), adjusted diluted EPS of $5.10 to $5.20, and an adjusted operating margin of about 23.5%. Q3 adjusted EPS is guided to $1.28 to $1.32. The company also declared its 406th consecutive quarterly dividend of $0.59 per share, payable August 15, 2025, and announced a new cardiovascular manufacturing facility in Georgia to be completed by 2028.

Jul 17, 2025 8-K

ABBOTT LABORATORIES 8-K Report, Executive Changes (May 1, 2025)

Abbott Laboratories (ABT) has filed a Form 8-K to report a significant executive change. Hubert L. Allen, Executive Vice President, General Counsel, and Secretary, has announced his intention to retire from the company. Mr. Allen's departure marks the end of an era for a key leadership position within Abbott, and the company will be undergoing a transition period to fill his role. While the filing itself does not provide details on a successor or the exact timeline for Mr. Allen's retirement, investors should monitor future communications from Abbott for updates on the leadership transition. The General Counsel and Secretary role is critical for corporate governance and legal oversight, making any changes in this position a point of focus for stakeholders concerned with the company's regulatory compliance and strategic direction.

May 1, 2025 8-K

ABBOTT LABORATORIES 8-K Report, Shareholder Vote Results (Apr 28, 2025)

Abbott Laboratories (ABT) has filed an 8-K detailing the outcomes of its Annual Meeting of Shareholders held on April 25, 2025. The primary focus of this filing is the voting results on key corporate matters. Notably, all proposed directors were re-elected to the Board, with the vast majority of votes cast in favor of each nominee. Additionally, shareholders overwhelmingly ratified the appointment of Ernst & Young LLP as the company's independent auditor for the upcoming fiscal year, indicating strong confidence in the current audit process and oversight. The advisory vote on executive compensation also passed, with nearly 90% of cast votes approving the compensation of named executive officers. While this vote is non-binding, it signals shareholder satisfaction with the company's remuneration policies. The filing provides detailed breakdowns of votes for, against, abstentions, and broker non-votes for each resolution, offering transparency into shareholder sentiment.

Apr 28, 2025 8-K

ABBOTT LABORATORIES 8-K Report, Financial Results (Apr 16, 2025)

Abbott Laboratories reported first-quarter 2025 results that beat its own growth profile and reaffirmed all full-year 2025 guidance. Net sales rose 4.0% reported to $10.358 billion, with organic growth of 6.9% (8.3% excluding COVID-19 testing sales). GAAP diluted EPS was $0.76, up 8.6%, and adjusted diluted EPS was $1.09, up 11.2%. Medical Devices was the primary engine, growing 9.9% reported and 12.6% organically, led by Diabetes Care (continuous glucose monitors up 18.3% reported to $1.7 billion), Structural Heart, Heart Failure and Electrophysiology. Operating earnings rose 22.1% to $1.693 billion, and adjusted gross and operating margins expanded by 140 and 130 basis points, respectively. The quarter had two offsetting pressures. Diagnostics fell 7.2% reported and 4.9% organically, reflecting a sharp drop in COVID-19 testing sales (to $84 million from $204 million) and China volume-based procurement; excluding COVID testing, Diagnostics grew 0.5%. Reported GAAP results were also affected by an approximately $200 million tax charge tied to adjustments to a previously recognized significant non-cash deferred tax benefit, which lifted the GAAP effective tax rate to 25.5% from 14.7% a year earlier. Management kept full-year guidance unchanged: organic sales growth of 7.5% to 8.5%, adjusted operating margin of 23.5% to 24.0%, and adjusted diluted EPS of $5.05 to $5.25, with second-quarter adjusted EPS guided to $1.23 to $1.27. The board also declared the 405th consecutive quarterly dividend of $0.59 per share, extending a 53-year streak of annual increases.

Apr 16, 2025 8-K

ABBOTT LABORATORIES 8-K Report, Financial Results (Jan 22, 2025)

Abbott Laboratories reported fourth-quarter 2024 sales of $11.0 billion, up 7.2% reported and 10.1% organic excluding COVID-19 testing, with full-year 2024 sales of $42.0 billion (up 4.6% reported, 9.6% organic excluding COVID-19 tests). Growth was led by Medical Devices (Q4 sales up 13.7%, with Diabetes Care and continuous glucose monitors, including FreeStyle Libre, driving results), while Diagnostics was pressured by lower COVID-19 testing demand and Established Pharmaceuticals and Nutrition grew modestly. Full-year adjusted diluted EPS was $4.67, at the upper end of initial guidance, while GAAP diluted EPS of $7.64 was inflated by a $7.497 billion non-cash tax valuation allowance release tied to restructuring of certain foreign affiliates. Investors should focus on the large gap between GAAP and adjusted results. The GAAP tax line was a benefit of $6.4 billion, producing a Q4 GAAP tax rate of -354.6%, versus an adjusted rate of about 15%. The adjusted figures exclude $1.878 billion of intangible amortization and about $755 million of other net expenses (impairments, restructuring, acquisition and divestiture items) for the full year. The GAAP EPS figure should therefore not be used as a run-rate measure of earnings power. For 2025, Abbott guided to organic sales growth of 7.5% to 8.5%, an adjusted operating margin of 23.5% to 24.0% (about 150 basis points of expansion at the midpoint), and adjusted diluted EPS of $5.05 to $5.25, implying double-digit growth at the midpoint. First-quarter 2025 adjusted EPS guidance is $1.05 to $1.09. The company also declared its 404th consecutive quarterly dividend of $0.59 per share, payable February 14, 2025, and noted 53 consecutive years of dividend increases.

Jan 22, 2025 8-K

ABBOTT LABORATORIES 8-K Report, Executive Changes (Nov 15, 2024)

Abbott Laboratories (ABT) has filed an 8-K report detailing the extension of its Change in Control Agreements with named executive officers. These agreements, originally set to expire on December 31, 2024, have been extended through December 31, 2026, following Abbott's notification to its executives on November 12, 2024. This extension is a proactive measure that provides continued stability and security for key leadership during a potentially transitional period, ensuring continuity in strategic direction and operations.

Nov 15, 2024 8-K

ABBOTT LABORATORIES 8-K Report, Financial Results (Oct 16, 2024)

Abbott Laboratories reported third-quarter 2024 results on October 16, 2024, with net sales of $10.6 billion, up 4.9% on a reported basis and 8.2% organically excluding COVID-19 testing sales. Growth was led by Medical Devices, where sales rose 11.7% reported and 13.3% organically, with Diabetes Care (including FreeStyle Libre continuous glucose monitors, which exceeded $1.6 billion in quarterly sales) and Structural Heart, Heart Failure, and Electrophysiology posting double-digit gains. Nutrition was roughly flat on a reported basis (down 0.3%) but grew 3.4% organically, with Adult Nutrition (Ensure) up 9.1% organically. Diagnostics declined 1.5% reported as COVID-19 testing sales fell to $265 million from $305 million, though excluding COVID tests, organic growth was 3.3%. Profitability was mixed. GAAP diluted EPS rose 14.6% to $0.94 and adjusted diluted EPS rose 6.1% to $1.21, with the gap driven by $470 million of intangible amortization and about $82 million of other specified items. Operating earnings grew 12.8% to $1.86 billion. For full-year 2024, Abbott raised the midpoint of its adjusted EPS guidance to $4.64-$4.70 and set GAAP EPS guidance at $3.34-$3.40, while maintaining its 9.5%-10.0% organic sales growth guidance excluding COVID-19 testing. Management indicated it expects to reach the upper end of initial guidance ranges. Abbott also authorized a new share repurchase program of up to $7 billion and declared a quarterly dividend of $0.55 per share, its 403rd consecutive quarterly dividend and the 52nd consecutive year of dividend increases. Key watch items include the sustainability of Medical Devices momentum, the continued decline in COVID-19 testing revenue, and the implied Q4 2024 adjusted EPS of $1.31-$1.37, which will test whether earnings growth can keep pace with the full-year guidance raise.

Oct 16, 2024 8-K

ABBOTT LABORATORIES 8-K Report, Financial Results (Jul 18, 2024)

Abbott Laboratories reported second-quarter 2024 results on July 18, 2024, with sales of $10.4 billion (up 4.0% reported, 7.4% organic, and 9.3% organic excluding COVID-19 testing). Growth was led by Medical Devices, where sales rose 10.2% reported and 12.1% organic, with double-digit gains in Diabetes Care (FreeStyle Libre), Electrophysiology, and Structural Heart. Nutrition grew 7.5% organically, while Diagnostics declined on a reported basis (-5.3%) as COVID-19 testing sales fell to $102 million from $263 million a year earlier. Excluding COVID-19 tests, Diagnostics grew 5.9% organically, with Core Laboratory up 8.8%. GAAP diluted EPS was $0.74, down 5.1% from $0.78, reflecting $0.40 per share of specified items, mainly intangible amortization ($471 million), restructuring, and acquisition and divestiture costs. Adjusted diluted EPS was $1.14, up 5.6% from $1.08. Net earnings fell 5.3% on a GAAP basis to $1.30 billion, while adjusted net earnings rose 5.8%. Operating earnings grew 8.2%, helped by lower amortization and a favorable swing in other income. Management raised full-year 2024 guidance. GAAP diluted EPS is now projected at $3.30 to $3.40 and adjusted diluted EPS at $4.61 to $4.71. Organic sales growth excluding COVID-19 testing was narrowed to 9.5% to 10.0%, which raises the midpoint. Third-quarter adjusted EPS is guided to $1.18 to $1.22. The board also declared a $0.55 quarterly dividend, the 402nd consecutive quarterly payment and the 52nd consecutive year of dividend increases.

Jul 18, 2024 8-K

ABBOTT LABORATORIES 8-K Report, Executive Changes (May 1, 2024)

Abbott Laboratories (ABT) announced the upcoming retirement of its Executive Vice President, Finance, Robert E. Funck, Jr., effective July 1, 2024. Mr. Funck's departure follows a distinguished 36-year career with the company. This transition marks the end of an era for a key financial executive, and investors will be keen to understand the succession plan and the impact on the company's financial leadership and strategy moving forward.

May 1, 2024 8-K

ABBOTT LABORATORIES 8-K Report, Shareholder Vote Results (Apr 29, 2024)

This 8-K filing from Abbott Laboratories (ABT) reports on the outcomes of its Annual Meeting of Shareholders held on April 26, 2024. The primary focus of the filing is the voting results on key corporate matters. Investors will note the overwhelming support for the re-election of the entire Board of Directors, with all nominees receiving a significant majority of the votes cast. The appointment of Ernst & Young LLP as the company's independent auditor was also overwhelmingly ratified. Finally, shareholders provided an advisory vote on the compensation of named executive officers, which passed with a strong majority, though this vote is non-binding. Overall, the results indicate continued shareholder confidence in the current leadership and governance structure of Abbott Laboratories. The robust support for the Board and auditors suggests a stable operating environment and alignment between management and its shareholders on fundamental corporate governance matters. While the executive compensation vote is advisory, the high approval rate is generally viewed as positive feedback on the company's pay practices.

Apr 29, 2024 8-K

Material AgreementsFinancial Events

ABBOTT LABORATORIES 8-K Report, Financial Results (Apr 17, 2024)

Abbott Laboratories (ABT) reported first-quarter 2024 results on April 17, 2024, with sales of $9.964 billion, up 2.2% reported and 10.8% organic excluding COVID-19 testing sales, marking the fifth consecutive quarter of double-digit organic growth in its underlying base business. Growth was led by Medical Devices (sales up 14.2% reported, with Diabetes Care, Electrophysiology, Neuromodulation and Structural Heart all growing double digits) and Established Pharmaceuticals (organic growth of 13.7%). Nutrition grew 5.1% reported, driven by Pediatric Nutrition in the U.S. The headline reported growth was held back by a steep decline in COVID-19 testing sales, which fell to $204 million from $730 million a year earlier, weighing heavily on Diagnostics, where reported sales fell 17.6%. Profitability was weaker on a GAAP basis. Diluted GAAP EPS was $0.70, down 6.7% from $0.75, and net earnings fell 7.0% to $1.225 billion. Adjusted diluted EPS, which excludes specified items such as intangible amortization, restructuring and acquisition costs, was $0.98, down 4.9% from $1.03. Operating earnings declined 8.1%, as SG&A rose 7.1% and cost of products sold rose 3.0%, outpacing sales growth. Management nonetheless narrowed its full-year 2024 guidance and raised the midpoint, now projecting GAAP diluted EPS of $3.25 to $3.40 and adjusted diluted EPS of $4.55 to $4.70, and projected organic sales growth excluding COVID-19 testing of 8.5% to 10.0%. Abbott also declared its 401st consecutive quarterly dividend of $0.55 per share, payable May 15, 2024. For investors, the key takeaways are the strength of the underlying growth engine in devices and emerging-market pharma against a shrinking COVID testing revenue base, and the question of whether margin and expense pressure will ease as the year progresses. Second-quarter guidance calls for adjusted EPS of $1.08 to $1.12 and GAAP EPS of $0.69 to $0.73.

Apr 17, 2024 8-K

ABBOTT LABORATORIES 8-K Report, Material Agreement (Jan 29, 2024)

Abbott Laboratories (ABT) has entered into a new Five Year Credit Agreement, establishing a $5 billion unsecured revolving credit facility. This new agreement replaces a similar facility that was set to mature in November 2025. Notably, there were no outstanding borrowings under the previous agreement at the time of its termination, and as of the filing date, there are no outstanding borrowings under the new facility. This action indicates Abbott's proactive approach to maintaining strong liquidity and financial flexibility. The new credit agreement allows for borrowings based on either a base rate or SOFR rate, with interest margins tied to Abbott's credit ratings. The company also acknowledges customary fees associated with such agreements. The termination of the old agreement and the establishment of the new one are standard financial management practices, ensuring continued access to capital for operational needs or strategic initiatives without immediate financial commitment.

Jan 29, 2024 8-K

ABBOTT LABORATORIES 8-K Report, Financial Results (Jan 24, 2024)

Abbott reported fourth-quarter 2023 reported sales of $10.241 billion, up 1.5% year over year. Organic growth was 2.1%, and 11.0% excluding COVID-19 testing sales, which fell from $1.069 billion to $288 million. Fourth-quarter GAAP diluted EPS was $0.91 (up 54.2%), and adjusted diluted EPS was $1.19 (up 15.5%). Growth was led by Medical Devices (reported +17.5%, with Diabetes Care and Electrophysiology strong), Nutrition (+12.2%, with U.S. infant formula share recovery), and Established Pharmaceuticals (+0.5% reported, +8.8% organic). For full-year 2023, reported sales fell 8.1% to $40.109 billion, driven by the expected decline in COVID-19 testing. Excluding COVID-19 tests, organic sales grew 11.6%. Full-year GAAP diluted EPS was $3.26 (down 16.6%), and adjusted diluted EPS was $4.44 (down 16.9%). Diagnostics fell 39.4% on reported sales, while Medical Devices rose 14.1% and Nutrition rose 9.3%. For 2024, Abbott guided to GAAP diluted EPS of $3.20 to $3.40 and adjusted diluted EPS of $4.50 to $4.70, implying roughly 1% to 6% adjusted EPS growth. Specified items are projected at about $1.30 per share, mainly intangible amortization. Organic sales growth excluding COVID-19 testing is projected at 8% to 10%. The company also declared its 400th consecutive quarterly dividend of $0.55 per share and noted 52 consecutive years of dividend increases.

Jan 24, 2024 8-K

ABBOTT LABORATORIES 8-K Report, Financial Results (Oct 18, 2023)

Abbott Laboratories reported third-quarter 2023 results on October 18, 2023, with net sales of $10.1 billion, down 2.6% reported, as expected declines in COVID-19 testing sales offset strong growth elsewhere. Management emphasized an organic sales growth rate of 13.8% excluding COVID-19 tests, with double-digit growth across all four major businesses. Nutrition (up 18.1% organic), Medical Devices (up 14.7% organic, led by Diabetes Care, Electrophysiology, Structural Heart and Neuromodulation) and Established Pharmaceuticals (up 11.1% organic) drove the underlying performance, while Diagnostics fell 31.9% organically but grew 10.1% excluding COVID-19 testing. Worldwide COVID-19 testing sales fell to $305 million from $1.671 billion a year earlier. Profitability was mixed on a reported basis. GAAP diluted EPS was $0.82 (up 1.2%), while adjusted diluted EPS excluding specified items was $1.14 (down 0.9%). Operating earnings fell 7.0% and R&D spending dropped 14.0%. For full-year 2023, Abbott narrowed GAAP EPS guidance to $3.14-$3.18 and adjusted EPS guidance to $4.42-$4.46, raising the midpoint of the adjusted range. The company also projects roughly $1.5 billion in full-year COVID-19 testing sales and low double-digit organic growth excluding those sales. For investors, the filing shows a company whose core base business is accelerating while the pandemic-related revenue unwind weighs on reported figures. Nine-month results were down more sharply (sales down 11.0%, adjusted EPS down 24.6%), so the year-over-year comparison remains a headwind. The quarterly dividend of $0.51 per share was declared, extending Abbott's 399 consecutive quarterly payments and 51 consecutive years of dividend increases.

Oct 18, 2023 8-K/A

ABBOTT LABORATORIES 8-K/A Report, Shareholder Vote Results (Sep 1, 2023)

This 8-K filing is an amendment to a previous report filed on May 2, 2023, concerning Abbott Laboratories' (ABT) Annual Meeting of Shareholders held on April 28, 2023. The primary purpose of this amendment is to correct a typographical error in the reported number of shares cast against Michael F. Roman, a key executive. The amendment clarifies the voting results for Mr. Roman, providing updated figures for votes cast for, against, abstentions, and broker non-votes. For investors, this filing is largely administrative and confirms the original outcome of the shareholder vote regarding Mr. Roman's re-election. While the correction itself is minor and does not alter the overall outcome of the shareholder vote, it demonstrates Abbott's commitment to accurate reporting. The overwhelming majority of votes were cast in favor of Mr. Roman, indicating continued shareholder confidence in leadership.

Sep 1, 2023 8-K

ABBOTT LABORATORIES 8-K Report, Financial Results (Jul 20, 2023)

Abbott Laboratories reported second-quarter 2023 results that were weaker on a reported basis but showed clear strength in its underlying base business. Net sales were $9.978 billion, down 11.4% reported, driven by an anticipated decline in COVID-19 testing-related sales (about $263 million in Q2 2023 versus $2.324 billion a year earlier). Excluding COVID-19 tests, organic sales grew 11.5%, led by Medical Devices (+14.2% organic), Established Pharmaceuticals (+12.6%), and Nutrition (+9.9%). Diabetes Care, Electrophysiology, Structural Heart, and Neuromodulation each posted double-digit organic growth, and Freestyle Libre sales reached about $1.3 billion. GAAP diluted EPS was $0.78, down 31.6% from $1.14, while adjusted diluted EPS was $1.08, down 24.5% from $1.43. The decline reflects the loss of high-margin COVID testing volume and $0.30 per share of specified items, mainly intangible amortization. Management raised its outlook for the underlying base business but kept full-year adjusted EPS guidance at $4.30 to $4.50, offset by lower expected COVID testing contribution. GAAP EPS guidance is $3.02 to $3.22, and full-year COVID testing sales are now expected to be about $1.3 billion. The quarterly dividend of $0.51 per share was declared as the 398th consecutive quarterly payment, and Abbott has raised its dividend for 51 consecutive years. For investors, the central question is whether the base business growth can offset the roughly $8 billion annual COVID testing decline that Abbott faces. The disclosed organic growth in Medical Devices and Nutrition, along with recent FDA approvals such as TactiFlex and AVEIR DR, supports the growth narrative. Reported declines, the gap between GAAP and adjusted EPS, and the 2023 tax items (about $40 million in Q2 and $62 million year-to-date) warrant attention in assessing earnings quality.

Jul 20, 2023 8-K

ABBOTT LABORATORIES 8-K Report, Executive Changes (Jun 12, 2023)

Abbott Laboratories (ABT) has announced a significant leadership transition within its finance department, effective September 1, 2023. This 8-K filing details the appointments of key finance executives, including Robert E. Funck, Jr. as Executive Vice President, Finance. Philip P. Boudreau will step into the role of Senior Vice President, Finance and Chief Financial Officer, continuing to report to Mr. Funck. John A. McCoy, Jr. has been appointed Vice President, Controller. These appointments reflect a strategic alignment of financial leadership within Abbott. Mr. Boudreau's long tenure and extensive experience within the company, including his recent role as Vice President, Controller, position him well for his new CFO responsibilities. Mr. McCoy's background, including his recent role as Vice President, Treasurer, also provides a solid foundation for his new position as Controller. Investors should monitor how these leadership changes impact financial strategy and execution moving forward.

Jun 12, 2023 8-K/A

ABBOTT LABORATORIES 8-K/A Report, Shareholder Vote Results (Jun 9, 2023)

This 8-K/A filing from Abbott Laboratories serves as an amendment to their previous 8-K filing dated May 2, 2023, which reported on the outcomes of their Annual Meeting of Shareholders held on April 28, 2023. The key update relates to the compensation of named executive officers. Following the shareholder vote and in line with the Board of Directors' recommendation, Abbott has confirmed that an advisory vote on executive compensation will be conducted annually going forward. This decision means shareholders will have an ongoing opportunity to provide their non-binding input on the compensation packages of Abbott's top executives. While advisory in nature, these votes are closely watched by the Board and management and can influence future compensation decisions. Investors should note that this is a procedural update regarding the frequency of the "say-on-pay" vote, rather than a change in compensation policy itself.

Jun 9, 2023 8-K

ABBOTT LABORATORIES 8-K Report, Shareholder Vote Results (May 2, 2023)

Abbott Laboratories (ABT) filed an 8-K on May 2, 2023, detailing the results of its Annual Meeting of Shareholders held on April 28, 2023. The report confirms the election of all nominated directors to the Board and the ratification of Ernst & Young LLP as the company's independent auditor. Shareholder approval was also given for the advisory vote on executive compensation and for holding this vote annually. Importantly, several shareholder proposals were voted down. These included proposals related to lowering the threshold for calling special meetings, requiring an independent board chairman, disclosing lobbying expenditures, and adjusting executive compensation metrics to exclude legal/compliance costs. The overwhelming support for the company's nominees and auditor, along with the rejection of these specific shareholder initiatives, signals continued confidence from the majority of shareholders in the current governance and operational strategies of Abbott Laboratories.

May 2, 2023 8-K

ABBOTT LABORATORIES 8-K Report, Financial Results (Apr 19, 2023)

Abbott Laboratories reported first-quarter 2023 results that were dominated by the expected collapse in COVID-19 testing revenue. Reported net sales fell 18.1% to $9.7 billion, but the underlying base business grew 10.0% on an organic basis excluding COVID-19 tests, led by Medical Devices (+12.4% organic), Established Pharmaceuticals (+11.1%) and Nutrition (+10.3%). COVID-19 testing sales were $730 million versus $3.3 billion a year earlier. Profitability fell more sharply than sales: GAAP operating earnings dropped 48.2% and GAAP diluted EPS was $0.75 versus $1.37, while adjusted diluted EPS (excluding specified items such as $491 million of intangible amortization) was $1.03 versus $1.73, down 40.5%. Management raised its view of the underlying business but kept its full-year guidance unchanged. Projected 2023 GAAP diluted EPS remains $3.05 to $3.25 and adjusted EPS remains $4.30 to $4.50, with the company now citing a stronger base business offset by lower expected COVID-19 testing contribution. Abbott now expects COVID-19 testing-related sales of approximately $1.5 billion for the full year (versus $8.4 billion in 2022) and organic growth excluding those tests of at least high single digits. The quarterly dividend of $0.51 per share was also reaffirmed, extending a 397-quarter streak. For investors, the key issue is quality of the transition: the base business is growing at a double-digit organic pace and product launches (Navitor, TriClip, FreeStyle Libre integrations) are gaining traction, but the reported earnings decline is steep and the guidance relies on a sharp step-down in pandemic-related revenue. Investors will be watching whether the base business momentum persists and whether the lost COVID testing profit is replaced over the rest of 2023.

Apr 19, 2023 8-K

ABBOTT LABORATORIES 8-K Report, Bylaw Amendment (Feb 17, 2023)

Abbott Laboratories (ABT) has filed an 8-K report primarily detailing an amendment to its bylaws concerning the size of its Board of Directors. Effective April 28, 2023, the Board of Directors will be reduced from thirteen members to twelve persons. This change is administrative and does not appear to be tied to any immediate strategic shifts or financial performance indicators disclosed in this specific filing.

Feb 17, 2023 8-K

ABBOTT LABORATORIES 8-K Report, Financial Results (Jan 25, 2023)

Abbott Laboratories reported fourth-quarter 2022 sales of $10.1 billion, down 12.0% reported and 6.1% organic, as expected declines in COVID-19 testing revenue (Q4 COVID test sales fell to $1.069 billion from $2.319 billion) weighed on Diagnostics. Excluding COVID-19 testing, Q4 sales decreased 1.4% reported and rose 5.4% organic. GAAP diluted EPS was $0.59 versus $1.11 a year earlier, while adjusted diluted EPS (excluding specified items such as intangible amortization, restructuring, acquisition costs, and a voluntary recall) was $1.03 versus $1.32. Full-year 2022 sales rose 1.3% reported and 6.4% organic to $43.7 billion, with GAAP diluted EPS of $3.91 and adjusted EPS of $5.34, up 2.5%. Full-year 2023 guidance calls for GAAP diluted EPS from continuing operations of $3.05 to $3.25 and adjusted EPS of $4.30 to $4.50, implying specified items of about $1.25 per share. Management projects high-single-digit organic sales growth excluding COVID-19 testing, with COVID-19 testing sales of roughly $2.0 billion, reflecting the expected shift of the pandemic toward an endemic state. Growth drivers cited include Medical Devices, where Diabetes Care (FreeStyle Libre, with approximately $1.1 billion of quarterly sales) and Structural Heart posted strong growth, and a steady run of FDA approvals including Navitor TAVI, Eterna spinal cord stimulation, and Aveir leadless pacemaker. The quarter also reflected headwinds in Nutrition, where U.S. infant formula production disruptions at the Sturgis, Michigan facility weighed on Pediatric sales, and in China, where COVID-19 lockdowns and supply constraints affected Medical Devices. The company declared a quarterly dividend of $0.51 per share, its 396th consecutive quarterly dividend and 51st consecutive annual increase.

Jan 25, 2023 8-K

ABBOTT LABORATORIES 8-K Report, Bylaw Amendment (Dec 9, 2022)

Abbott Laboratories (ABT) filed an 8-K on December 9, 2022, to report the amendment and restatement of its by-laws, effective immediately. These changes primarily focus on updating and clarifying the procedural mechanics and information requirements for shareholder nominations of directors and shareholder proposals at meetings. This includes specific provisions related to Rule 14a-19 under the Exchange Act, which governs proxy access. The amendments also address special meetings, the powers of the Board and meeting Chair, and include other ministerial, conforming, and gender-neutrality updates. While these amendments are primarily procedural and do not alter Abbott's financial performance or strategic direction, they are important for shareholders to understand as they impact how shareholder actions can be brought forth and managed at company meetings. Investors should be aware that these changes are designed to ensure compliance with evolving regulations and to streamline meeting governance.

Dec 9, 2022 8-K

ABBOTT LABORATORIES 8-K Report, Executive Changes (Oct 21, 2022)

Abbott Laboratories (ABT) has filed an 8-K report on October 21, 2022, primarily addressing the extension of its Change in Control Agreements with its named executive officers. These agreements, originally set to expire on December 31, 2022, have been extended for an additional two years, now through December 31, 2024. This extension provides continuity and stability for key leadership during a period that could involve significant corporate events. For investors, this action signals Abbott's commitment to retaining its executive team and maintaining a stable leadership structure. The extension of these agreements suggests management's confidence in the company's future and its ongoing strategies. While the filing itself does not disclose specific financial performance or new business initiatives, it reassures stakeholders about leadership continuity, which is often a positive indicator for long-term strategic execution and stability.

Oct 21, 2022 8-K

Leadership ChangesCorporate ChangesExhibits & Filings

ABBOTT LABORATORIES 8-K Report, Financial Results (Oct 19, 2022)

Abbott Laboratories reported third-quarter 2022 results on October 19, 2022, with worldwide sales of $10.4 billion, down 4.7% on a reported basis but up 1.3% organically. The decline was driven largely by lower COVID-19 testing-related sales (about $1.67 billion in 3Q22 versus $1.91 billion in 3Q21), a manufacturing stoppage at the Sturgis, Michigan infant formula plant earlier in 2022, and China COVID lockdowns. Excluding COVID testing and the Sturgis-related U.S. impact, worldwide sales fell 0.6% reported and rose 6.0% organically, which suggests the underlying business is healthier than the headline figures show. GAAP diluted EPS was $0.81, down 30.8% year over year, while adjusted diluted EPS excluding specified items was $1.15, down 17.9%. Specified items were mainly intangible amortization ($498 million pre-tax), an R&D intangible impairment, acquisition costs, and recall-related costs. Management raised full-year 2022 guidance: GAAP EPS of $3.75 to $3.81 and adjusted EPS of $5.17 to $5.23. Full-year guidance assumes $7.8 billion of COVID testing sales, of which $7.3 billion has already been recorded through September, leaving only about $0.5 billion expected in the fourth quarter. Segment performance was mixed. U.S. Medical Devices grew 11.3% reported, led by Electrophysiology, Structural Heart and Diabetes Care, and FreeStyle Libre U.S. sales grew more than 40%. Nutrition fell 14.9% reported (down 10.3% organic), and Diagnostics fell 6.2% reported as COVID testing declined. Established Pharmaceuticals grew 12.2% organically. The board also declared a quarterly dividend of $0.47 per share, extending Abbott's streak to 395 consecutive quarters and 50 consecutive years of dividend increases.

Oct 19, 2022 8-K

ABBOTT LABORATORIES 8-K Report, Executive Changes (Sep 15, 2022)

Abbott Laboratories (ABT) filed an 8-K on September 15, 2022, primarily announcing two key governance changes. The company appointed Claire Babineaux-Fontenot to its Board of Directors, effective September 15, 2022. This addition brings new expertise and perspectives to the board's oversight. In conjunction with this appointment, Abbott's Board of Directors also amended its bylaws to increase the size of the board from twelve to thirteen members. This adjustment provides the necessary capacity for the new director and allows for potential future expansion. Investors should view these as routine corporate governance actions aimed at strengthening the board's composition and effectiveness.

Sep 15, 2022 8-K

ABBOTT LABORATORIES 8-K Report, Financial Results (Jul 20, 2022)

Abbott Laboratories reported second-quarter 2022 results on July 20, 2022, with net sales of $11.3 billion, up 10.1% on a reported basis and 14.3% on an organic (constant-currency) basis. The headline growth was driven by COVID-19 testing, with Diagnostics sales up 36.9% organically and roughly $2.3 billion of global COVID-19 testing-related sales. Excluding COVID-19 testing, worldwide sales fell 0.3% reported (up 4.1% organically), and the company also cited a February voluntary recall and manufacturing shutdown of certain infant formula products that weighed on Nutrition, which fell 4.5% organically. Profitability was strong. GAAP diluted EPS rose 72.7% to $1.14, and diluted EPS excluding specified items rose 22.2% to $1.43. Operating earnings increased 70.6% to $2.38 billion, though the comparison is flattered by a prior-year $500 million restructuring charge tied to COVID-19 diagnostics manufacturing. Medical Devices grew 7.5% organically, with Diabetes Care strong (FreeStyle Libre about $1.1 billion, up 25.6% organically) while cardiovascular and neuromodulation procedure volumes were hurt by COVID-19 surges and China lockdowns. Management raised full-year 2022 guidance to GAAP diluted EPS of at least $3.50 and adjusted diluted EPS of at least $4.90, and projects $6.1 billion of COVID-19 testing sales for the year, including $5.6 billion already booked through June. Investors should note that a large share of the upside depends on COVID-19 testing demand, which is expected to fade, and that the company declared its 394th consecutive quarterly dividend of $0.47 per share, payable August 15, 2022.

Jul 20, 2022 8-K

ABBOTT LABORATORIES 8-K Report, Shareholder Vote Results (May 2, 2022)

This 8-K filing from Abbott Laboratories details the outcomes of its Annual Meeting of Shareholders held on April 29, 2022. Key investor-focused information includes the overwhelming re-election of the entire Board of Directors and the ratification of Ernst & Young LLP as the company's auditor. Shareholders also approved the compensation of named executive officers in an advisory vote. The filing also outlines several shareholder proposals that were rejected by the majority of votes cast, including proposals related to special meeting thresholds, independent board chair, Rule 10b5-1 plans, lobbying expenditures, and antimicrobial resistance reporting. From an investor's perspective, the broad support for the board and auditor indicates a level of confidence in current management and governance. The rejection of most shareholder proposals suggests that the board's current strategies and policies are favored by the majority of shareholders, or at least that the proposals did not garner sufficient support to pass. The advisory vote on executive compensation passing with over 91% approval is a positive signal regarding shareholder alignment on pay practices.

May 2, 2022 8-K

ABBOTT LABORATORIES 8-K Report, Financial Results (Apr 20, 2022)

Abbott Laboratories reported first-quarter 2022 results on April 20, 2022, with net sales of $11.9 billion, up 13.8% reported and 17.5% organic. The headline growth was driven largely by COVID-19 testing: global COVID-19 testing-related sales were $3.3 billion in the quarter. Excluding those sales, reported growth was 3.9% and organic growth was 7.7%, which is the more representative view of the core business. Medical Devices (+11.5% organic) and Established Pharmaceuticals (+13.4% organic) were the standout segments, while Nutrition declined 4.4% organic, weighed down by the voluntary infant formula recall and challenging pediatric conditions in China. Profitability was strong on a reported basis. GAAP diluted EPS was $1.37, up 37.0%, and adjusted diluted EPS (excluding specified items such as $512 million of intangible amortization and $211 million of other net expenses, including recall costs and acquisition-related charges) was $1.73, up 31.1%. Operating earnings rose 38.1% to $2.9 billion. Abbott maintained its adjusted EPS guidance of at least $4.70 for 2022 but raised the bar on GAAP EPS framing by projecting at least $3.35 (versus the specified-items gap of $1.35 per share). Guidance continues to include roughly $4.5 billion of COVID-19 testing sales, expected to be concentrated in the first half of 2022. For investors, the key takeaways are the quality of earnings and the sustainability of the COVID-19 revenue tailwind. The quarter demonstrates underlying strength in Diagnostics ex-COVID, Diabetes Care (FreeStyle Libre sales of about $1.0 billion), and Electrophysiology, but also highlights ongoing risk in Nutrition and reliance on episodic pandemic demand. Abbott also declared its 393rd consecutive quarterly dividend of $0.47 per share, payable May 16, 2022, and it remains a 50-year consecutive dividend increaser.

Apr 20, 2022 8-K

ABBOTT LABORATORIES 8-K Report, Bylaw Amendment (Feb 22, 2022)

Abbott Laboratories (ABT) has filed an 8-K report primarily detailing an amendment to its bylaws concerning the size of its Board of Directors. Effective April 29, 2022, the Board of Directors will be reduced from thirteen to twelve members. This change, approved by the Board of Directors on February 18, 2022, revises Article III, Section 2 of Abbott's bylaws. While this is a procedural change related to corporate governance, investors should note that such adjustments in board size can sometimes precede or accompany other strategic shifts, though no specific strategic implications are mentioned in this filing. The filing also includes updated bylaws and cover page interactive data. The report was signed by Robert E. Funck, Jr., Executive Vice President, Finance and Chief Financial Officer.

Feb 22, 2022 8-K

Regulation FD

ABBOTT LABORATORIES 8-K Report, Regulation FD Disclosure (Feb 18, 2022)

Abbott Laboratories (ABT) filed an 8-K on February 18, 2022, disclosing a proactive, voluntary recall of Similac-brand powder infant formulas manufactured at its Sturgis, Michigan facility. This recall primarily affects products distributed in the U.S. and Canada. While the company is confirming its previously issued full-year 2022 guidance for adjusted diluted earnings per share from continuing operations at $4.70 or more, it anticipates a one-time expense in the first quarter of 2022 related to recall expenses, including inventory destruction. Despite these recall-related costs, Abbott does not expect the expenses to have a material impact on its consolidated financial statements. The company has issued a press release to inform consumers about the recall. Investors should note that while the company is reiterating its full-year earnings guidance, the undisclosed but expected expenses in Q1 2022 related to this recall warrant attention for short-term financial impacts.

Feb 18, 2022 8-K

ABBOTT LABORATORIES 8-K Report, Financial Results (Jan 26, 2022)

Abbott Laboratories reported strong fourth-quarter and full-year 2021 results, with fourth-quarter sales of $11.5 billion (up 7.2% reported, 7.7% organic) and full-year sales of $43.1 billion (up 24.5% reported, 22.9% organic). Growth was heavily buoyed by COVID-19 testing, which contributed $2.3 billion in Q4 and $7.7 billion for the full year. Excluding COVID-19 testing, fourth-quarter sales grew 9.6% reported (10.3% organic). Fourth-quarter GAAP diluted EPS from continuing operations was $1.11, down 7.5% year over year, while adjusted diluted EPS was $1.32, down 9.0%. For the full year, GAAP diluted EPS from continuing operations rose 58.2% to $3.94 and adjusted EPS rose 42.7% to $5.21, though much of the full-year earnings lift reflects the pandemic testing windfall and a lower prior-year base. The fourth-quarter profit decline was driven by higher SG&A (up 18.6%) and cost of products sold, which outpaced sales growth, with GAAP operating earnings falling 2.2%. Within segments, Diagnostics was the swing factor: U.S. sales rose 20.5% on strength in non-COVID areas and the company's FreeStyle Libre franchise, while international Diagnostics fell 11.8% as COVID testing demand declined. Medical Devices grew 15.1% reported, led by Diabetes Care, Heart Failure and Structural Heart. Nutrition grew 5.5% and Established Pharmaceuticals grew 4.9%, with China weakness weighing on international pediatric nutrition. Looking ahead, Abbott guided 2022 GAAP diluted EPS from continuing operations to at least $3.43 and adjusted diluted EPS to at least $4.70, and it forecast Q1 2022 adjusted EPS of at least $1.50. The 2022 outlook includes an initial $2.5 billion of COVID-19 testing sales expected early in the year, which the company will update quarterly. The company also declared its 392nd consecutive quarterly dividend of $0.47 per share, payable February 15, 2022, and noted 50 consecutive years of dividend increases.

Jan 26, 2022 8-K